123
Participants
Start Date
January 12, 2023
Primary Completion Date
May 1, 2030
Study Completion Date
November 1, 2030
Ocrelizumab
Two 300 mg intravenous (IV) OCR infusions separated by 14 days (i.e., Days 0 and 14) for a total of 600 mg, followed by 600 mg OCR infusions every 6 months from Month 6 through Month 48.
Placebo for Ocrelizumab
Placebo infusions every 6 months from Month 30 through Month 48.
RECRUITING
Icahn School of Medicine at Mount Sinai, New York
RECRUITING
University of Rochester Medical Center, Rochester
RECRUITING
University of Pennsylvania, Perelman School of Medicine, Philadelphia
RECRUITING
MedStar Georgetown University Hospital, Washington D.C.
RECRUITING
Virginia Commonwealth University School of Medicine, Richmond
RECRUITING
Oklahoma Medical Research Foundation, Oklahoma City
RECRUITING
University of Texas Southwestern Medical Center, Dallas
RECRUITING
The University of Texas Health Science Center at Houston, McGovern Medical School, Houston
RECRUITING
Yale School of Medicine, New Haven
RECRUITING
Massachusetts General Hospital, Boston
RECRUITING
University of Massachusetts Memorial Medical Center, Worcester
Collaborators (1)
Autoimmunity Centers of Excellence (ACE)
UNKNOWN
Rho Federal Systems Division, Inc.
INDUSTRY
Genentech, Inc.
INDUSTRY
National Institute of Allergy and Infectious Diseases (NIAID)
NIH